Description:
This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.
Sponsor:
Fudan University
Contacts:
Jiong Wu, MDwujiong1122@vip.sina.com
+862164175590 ext 88607
Government Study Link:
NCT04281641 - Click here to see study onClinicalTrials.gov